C3 Glomerulopathy

19 registered clinical trials studyying C3 Glomerulopathy — 10 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Study of NM8074 in Adult C3 Glomerulopathy Patients NCT05647811	NovelMed Therapeutics	Phase 1 / Phase 2
Not Yet Recruiting	A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 Glomerulopathy NCT07416162	Novartis Pharmaceuticals	—
Not Yet Recruiting	CHART-C3G/CLNP023B12011 NCT07331259	Novartis Pharmaceuticals	—
Recruiting	Fabhalta Capsules Specified Drug-use Survey NCT07156149	Novartis Pharmaceuticals	—
Recruiting	Home Reported Outcomes in C3G Study NCT07029542	Novartis Pharmaceuticals	—
Not Yet Recruiting	A Study of SGB-9768 in Patients with Complement-mediated Kidney Diseases NCT06786338	Suzhou Sanegene Bio Inc.	Phase 2
Recruiting	Safety and Efficacy Study of OMS906 in Patients With C3G and ICGN NCT06209736	Omeros Corporation	Phase 2
Active Not Recruiting	An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Peg NCT05809531	Apellis Pharmaceuticals, Inc.	Phase 3
Completed	Study of ARO-C3 in Adult Healthy Volunteers and Patients With Complement Mediated Renal Disease NCT05083364	Arrowhead Pharmaceuticals	Phase 1 / Phase 2
Completed	Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immun NCT05067127	Apellis Pharmaceuticals, Inc.	Phase 3
Active Not Recruiting	Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN NCT04572854	Apellis Pharmaceuticals, Inc.	Phase 2
Recruiting	Evaluation of a Renin Inhibitor, Aliskiren, Compared to Enalapril, in C3 Glomerulopathy NCT04183101	Region Skane	Phase 2
Recruiting	Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN NCT03955445	Novartis Pharmaceuticals	Phase 3
Completed	Non-contrast Enhanced MRI in Patients With C3 Glomerulopathy (C3G) or Immune-complex Membranoproliferative Glo NCT03723512	Mario Negri Institute for Pharmacological Research	N/A
Terminated	A Proof of Concept Study for a 12 Month Treatment in Patients With C3G or IC-MPGN Treated With ACH-0144471 NCT03459443	Alexion Pharmaceuticals, Inc.	Phase 2
Completed	A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants With C3 Glomerulopathy (C3G) NCT03369236	Alexion Pharmaceuticals, Inc.	Phase 2
Completed	A Proof-of-Mechanism Study to Determine the Effect of Danicopan on C3 Levels in Participants With C3G or IC-MP NCT03124368	Alexion Pharmaceuticals, Inc.	Phase 2
Recruiting	National Registry of Rare Kidney Diseases NCT06065852	UK Kidney Association	—
Approved For Marketing	C3G/Primary IC-MPGN EAP NCT04729062	Apellis Pharmaceuticals, Inc.	—